Live Feeds
● LIVE Updated 2h ago · 6 sources tracked

A biotech hedge fund births a new immunology company

North Immunology is entering the public market through a reverse merger with Aethlon Medical. The combined entity aims to advance a novel IL-13 x IL-18 bispecific antibody designed to treat atopic dermatitis. The drug is currently moving toward clinical trials. This venture was initiated by a biotech hedge fund to establish the immunology company.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (6)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ North Immunology and Aethlon Medical announced a merger to advance a novel IL-13 x IL-18 bispecific antibody for atopic dermatitis.
  • ✓ North Immunology is going public via a reverse merger as its eczema drug moves toward the clinic.
🛡️ Source Corroboration: 6 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

North Immunology and Aethlon Medical announced a merger to develop a bispecific antibody for eczema.

Live updates

  1. North Immunology goes public via merger with Aethlon Medical

    North Immunology is entering the public market through a reverse merger with Aethlon Medical. The combined entity aims to advance a novel IL-13 x IL-18 bispecific antibody designed to treat atopic dermatitis. The drug is currently moving toward clinical trials. This venture was initiated by a biotech hedge fund to establish the immunology company.

    Why it matters

    Atopic dermatitis, commonly known as eczema, requires targeted immunotherapies to manage inflammation. A reverse merger allows a private company to bypass the traditional IPO process to gain public listing and capital.

    What is confirmed

    • North Immunology and Aethlon Medical announced a merger to advance a novel IL-13 x IL-18 bispecific antibody for atopic dermatitis.
    • North Immunology is going public via a reverse merger as its eczema drug moves toward the clinic.

    Still unconfirmed

    • A biotech hedge fund founded North Immunology.
    • Halper Sadeh LLC is investigating if AEMD, CSR, and ATKR are obtaining fair deals for their shareholders.

    What to watch next

    • Clinical trial start dates for the IL-13 x IL-18 bispecific antibody.
    • Outcome of the Halper Sadeh LLC investigation into shareholder deal fairness.
    Sources used for this update (6)
    1. STAT — A biotech hedge fund births a new immunology company
    2. Yahoo Finance — Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis
    3. Fierce Biotech — North Immunology goes public via reverse merger as eczema drug heads toward clinic
    4. globenewswire.com — Halper Sadeh LLC is Investigating Whether AEMD, CSR, ATKR are Obtaining Fair Deals for their Shareholders
    5. Stock Titan — Haymaker Acquisition Corp V SEC Filing (Sep 17, 2026)
    6. www.statnews.com — Trump touts pharma deals to offer cheaper drugs to state Medicaid programs
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community